KR102571040B1 - Composition inducing bone regeneration of implant placement and manufacturing method thereof - Google Patents

Abstract

The present invention relates to a composition for inducing osteogenesis in an implant placement part and a method for manufacturing the same, and more particularly, the composition is formed on a base layer made of a magnesium mesh and at least one of an outer surface and an inner surface of the base layer, It consists of a cortical layer made of a hydrogel containing at least one selected from the group consisting of an osteoclast proliferation inhibitor and an osteoblast proliferation promoter. In addition, the composition is 2-hydroxyethyl methacrylate, methacrylic anhydride, polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2,2-dimethoxy-2-phenylacetophenone, and purified water or acidic solution After mixing and injecting into a mold, a hydrogel preparation step of crosslinking by irradiating ultraviolet rays, a dilution step of diluting at least one selected from the group consisting of an osteoclast proliferation inhibitor and an osteoblast proliferation promoter in purified water or an acidic solution, and It is prepared through a hydrogel impregnation step of impregnating the hydrogel prepared through the hydrogel preparation step into the diluent prepared through the dilution step.
The above composition for inducing osteogenesis in the implant placement part and its manufacturing method are applied to the jawbone where the implant is placed to inhibit the proliferation of osteoclasts and promote the proliferation of osteoblasts to improve bone density, thereby improving the efficiency of implant placement. show effect.

Description

Composition for inducing osteogenesis in the implant placement area and method for manufacturing the same

The present invention relates to a composition for inducing osteogenesis in an implant placement part and a method for manufacturing the same, and more particularly, when applied to an implant placement part, it inhibits resorption of damaged basal bone around the placement part by osteoclasts and also promotes osteoblast cell growth. It relates to a composition for inducing osteogenesis for the placement of an implant having a proliferation-stimulating effect and a manufacturing method thereof.

Dental implant refers to a treatment that makes a tooth root and prosthesis in the area missing due to an accident or dental caries to make it look like a natural tooth. It is a procedure that directly embeds a tooth and then forms a crown on top of it to play the same role as a natural tooth.

In implant prosthesis, a fixture (artificial tooth root) implanted in the alveolar bone and serving as the root of a tooth, an abutment (abutment) connecting the artificial tooth root and the prosthesis, and an artificial crown prosthesis made to match adjacent teeth ( crown).

The fixture is fixed to the jawbone, and when a metal such as titanium, which is known to be osseointergration, is processed or molded into a screw shape and inserted into a hole formed in the jawbone in advance, the jawbone and the fixture adhere to the root of the tooth. plays the role of

However, in the case of people with low bone density, severe bone resorption, or slow bone regeneration, such as the elderly, since the fixture may not be properly fixed to the jawbone, the process of transplanting artificial bones such as autogenous bone, allogeneic bone, and synthetic bone have to go through At this time, the bone graft material implanted in the jawbone needs to be replaced with autogenous bone as it is absorbed, so it takes a long time. is applied as However, since the titanium mesh is bioinert and there is the inconvenience of having to perform a secondary operation for removal after the bone graft material is ossified, a bioabsorbable magnesium mesh has recently been considered. However, since the magnesium mesh cannot form a nanotube layer on the surface like the titanium mesh, there are limitations in loading drugs that control bioactivity, inhibit bone resorption, or promote new bone formation.

Therefore, in order to solve the above problem, the present inventors prepared a hybrid gel by adding HEMA (2-Hydroxyethyl methacrylate) and methacrylic anhydride (MA) to a hydrogel, which is an amphiphilic block copolymer, and then loaded the drug with magnesium By applying it together with the mesh, it was confirmed that the initial retention of the implant can be dramatically improved along with bone regeneration when the magnesium mesh application part is applied, and the present invention was completed.

Korean Patent Registration No. 10-0644296 (2006.11.02. Notice) Korean Patent Publication No. 10-2012-0074087 (published on July 5, 2012)

An object of the present invention is to provide a composition for inducing osteogenesis in an implant placement part and a method for manufacturing the same, which dramatically improve the initial retention after implant implantation or when bone mass is insufficient in the jawbone where the implant is placed.

An object of the present invention is to provide a substrate layer made of a magnesium mesh and a skin layer made of a hybrid gel applied to at least one of the outer and inner surfaces of the substrate layer and containing at least one of an osteoclast growth inhibitor and an osteoblast growth promoter. It is achieved by providing a composition for inducing osteogenesis of the implant placement part, characterized in that consisting of.

According to a preferred feature of the present invention, the hydrogel is 2-hydroxyethyl methacrylate, methacrylic anhydride, polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2,2-dimethoxy-2-phenyl It should consist of acetophenone and purified water.

According to a more preferred feature of the present invention, the hydrogel is 2-hydroxyethyl methacrylate 57 to 87% by weight, methacrylic anhydride 1.5 to 2.5% by weight, polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer 8 to 32% by weight, 2 to 8% by weight of 2,2-dimethoxy-2-phenylacetophenone, and the remaining amount of purified water.

According to a more preferred feature of the present invention, the osteoclast proliferation inhibitor is composed of at least one selected from the group consisting of, but not necessarily limited to, bisphosphonate-based drugs and denosumab.

According to a more preferred feature of the present invention, the osteoblast proliferation promoter consists of at least one selected from the group consisting of, but not necessarily limited to, teriparatide and strontium ranelate.

In addition, an object of the present invention is 2-hydroxyethyl methacrylate, methacrylic anhydride, polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2,2-dimethoxy-2-phenylacetophenone, and purified water Alternatively, a hydrogel manufacturing step of mixing an acidic solution and injecting it into a molding mold and crosslinking by irradiating ultraviolet rays, a dilution step of diluting at least one selected from the group consisting of an osteoclast growth inhibitor and an osteoblast growth promoter in purified water or physiological saline, and a drug loading step (S105) of impregnating the hydrogel prepared through the hydrogel manufacturing step (S101) into the diluent prepared through the dilution step (S105). It can also be achieved by providing

According to a preferred feature of the present invention, the hydrogel preparation step includes 57 to 87% by weight of 2-hydroxyethyl methacrylate, 1.5 to 2.5% by weight of methacrylic anhydride, polyethylene oxide-polypropylene oxide-polyethylene oxide ternary air It is made by mixing 8 to 32% by weight of the copolymer, 2 to 8% by weight of 2,2-dimethoxy-2-phenylacetophenone, and the remaining amount of purified water.

According to a more preferred feature of the present invention, the acidic solution of the hydrogel production step is an acidic solution of pH 1 to 5.

According to a more preferred feature of the present invention, the ultraviolet irradiation is made by irradiating ultraviolet rays having a wavelength of 360 to 370 nm for 15 to 25 minutes.

According to a more preferred feature of the present invention, the dilution step is made by mixing 1 to 1.5 parts by weight of at least one selected from the group consisting of an osteoclast growth inhibitor and an osteoblast growth promoter in 100 parts by weight of purified water.

According to a more preferred feature of the present invention, the hydrogel impregnation step is to be made for 20 to 30 hours.

According to a more preferred feature of the present invention, between the hydrogel manufacturing step and the hydrogel impregnation step, the hydrogel prepared through the hydrogel manufacturing step is immersed in distilled water for 70 to 75 hours to remove unreacted substances. It is assumed that the reactant removal step further proceeds.

The composition for inducing osteogenesis in the implant placement part and the manufacturing method according to the present invention are applied to the jawbone where the implant is placed to reduce the function of osteoclasts that induce bone resorption or promote the activity of osteoblasts, thereby increasing the rate of bone regeneration and Because it improves bone density, it increases the retention force at the initial stage of implant placement, so there is an effect of improving the efficiency of implant placement.

1 is a perspective view showing a composition for inducing osteogenesis of an implant placement unit according to the present invention.
Figure 2 is a flow chart showing a method for manufacturing a composition for inducing osteogenesis in the implant placement unit according to an embodiment of the present invention.
3 is a flow chart showing a method for manufacturing a composition for inducing osteogenesis in an implant placement unit according to another embodiment of the present invention.
Figure 4 is a graph showing the amount of release of sodium ibandronate, an osteoclast growth inhibitor, contained in the composition for inducing osteogenesis in the implant placement part prepared in Examples 1 to 4 of the present invention over time.

Hereinafter, a preferred embodiment of the present invention and the physical properties of each component will be described in detail, but this is to be explained in detail so that a person having ordinary knowledge in the art to which the present invention belongs can easily practice the invention, This is not meant to limit the technical spirit and scope of the present invention.

As shown in FIG. 1 below, the composition for inducing osteogenesis of an implant placement part according to the present invention is formed on a base layer 10 made of a magnesium mesh and at least one of the outer and inner surfaces of the base layer 10, It consists of a cortical layer 20 made of a hydrogel containing at least one of an osteoclast growth inhibitor and an osteoblast growth promoter.

The magnesium mesh applied as the substrate layer 10 serves to gather bone graft materials to be transplanted into the jawbone in one place, like the conventional titanium mesh, and to prevent the penetration of living soft tissue into the bone graft site. Since it is decomposed through oxidation after being applied to the part, it shows the advantage of not having to go through a separate removal process like titanium mesh.

However, since the magnesium mesh starts to decompose through oxidation after about a week has elapsed, time is insufficient for the bone graft material to take its place, and in addition, to improve the initial retention, the osteoclast growth inhibitor and osteoblast proliferation as described above are used. It is preferable to form the outer skin layer 20 made of a hydrogel containing any one or more of the accelerators.

The outer skin layer 20 is formed on the outer surface of the base layer 10, and is made of a hydrogel containing at least one of an osteoclast growth inhibitor and an osteoblast growth promoter.

The hydrogel is composed of 2-hydroxyethyl methacrylate, methacrylic anhydride, polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2,2-dimethoxy-2-phenylacetophenone, and purified water.

Preferably, the hydrogel contains 57 to 87% by weight of 2-hydroxyethyl methacrylate, 1.5 to 2.5% by weight of methacrylic anhydride, 8 to 32% by weight of polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, It is preferably composed of 2 to 8% by weight of 2,2-dimethoxy-2-phenylacetophenone and the balance of purified water.

The hydrogel composed of the above components is a hydrophilic material in which water-soluble polymers form a three-dimensional network structure by physical or chemical bonding. It absorbs a large amount of water and swells, but does not dissolve in water and maintains its shape, and has a high water content , porous structure, relatively soft physical properties, excellent biocompatibility, and physical similarity with extracellular matrix, it can be widely applied in biomedical fields such as drug delivery systems, tissue engineering scaffolds, and biosensors.

In general, a hydrogel with a hydrophilic polymer network structure is not easy to dissolve and deliver poorly soluble drugs, so a method using an amphiphilic block copolymer having both hydrophilic and hydrophobic properties should be considered. In the present invention, the hydrogel is hydrophilic as described above. Polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer composed of hydrophilic polyethylene oxide (PEO) and hydrophobic polypropylene oxide (PPO) as an amphiphilic block copolymer to have both hydrophobicity and used

In particular, due to its porous structure, the hydrogel composed of the above components slowly releases the osteoclast growth inhibitor or osteoblast growth promoter after the osteoclast growth inhibitor or osteoblast growth promoter is contained, thereby inhibiting the proliferation of osteoclasts for a long period of time. Or to show the effect of promoting the proliferation of osteoblasts.

The hydrogel is delicately composed of the same physical properties as the human outer skin or human cell substrate, and is a component that does not need to be removed separately after the procedure. It assists the functionality of the mesh and, as shown above, serves to ensure that hydrophilic and hydrophobic drugs are well loaded.

At this time, the osteoclast proliferation inhibitor is preferably composed of at least one selected from the group consisting of bisphosphonate-based drugs and denosumab.

Since the bisphosphonate-based drug has a high affinity for calcium and hydroxyapatite, it is easily attached to bone, and in the process of bone resorption, it is introduced into osteoclasts and decreases their function, thereby strongly suppressing bone resorption. and eventually induce apoptosis.

More specifically, since bisphosphonate drugs have a high affinity for calcium and hydroxyapatite, they are attached to bone and affect bone metabolism. In addition to apoptosis due to the destruction of the inner cytoskeleton and loss of bone resorption function, the differentiation of osteoclasts is inhibited and furthermore, since the activity of osteoclasts is inhibited by osteoblasts, bone resorption is strongly inhibited.

In addition, bisphosphonate-based drugs have a very low bioabsorption rate and only a small amount is absorbed when administered orally. For example, it is known that only about 0.7% of alendronate is absorbed.

Such bisphosphonate-based drugs include pamidronate, alendronate, risedronate, ibandronate, and zoledronate, which are used to treat postmenopausal osteoporosis patients, steroid-induced osteoporosis patients, and male osteoporosis.

In addition, denosumab is a monoclonal antibody to RANKL (Receptor activator of nuclear factor kappa-kB ligand) and serves to inhibit the activation of osteoclasts.

In general, osteoclasts are formed when RANKL of osteoblasts or activated immune cells binds to a receptor (RANK) located on osteoclasts. Since denosumab inhibits the activation of osteoclasts, osteoblasts or activated immune cells prevents RANKL from binding to osteoclast receptors.

In particular, it has been reported that when the bisphosphonate-based drug was loaded locally on the implant, more bone was formed earlier and higher bone-to-implant contact was shown than when it was not loaded. (Meraw et al., 1999; Zuffetti et al., 2009). Considering these points, when bisphosphonate drugs are released from the implant placement site immediately after dental implant implantation, the function of osteoclasts that cause early bone resorption in the implant placement site is inhibited, resulting in stable retention at the initial stage of implant placement. will be.

The osteoblast growth promoter includes teriparatide, strontium ranelate, and the like, and when the osteoblast growth promoter is released from the implant placement immediately after implantation of the dental implant, the osteoclasts in the implant placement It will be possible to obtain a stable retention force in the early stage of implant placement by suppressing the function of osteoblasts, promoting the function of osteoblasts, or treating osteoclast growth inhibitors and osteoblast growth promoters in a mixed state.

In addition, the preparation method of the composition for inducing osteogenesis at the implant placement site according to the present invention includes 2-hydroxyethyl methacrylate, methacrylic anhydride, polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2,2 -Dimethoxy-2-phenylacetophenone, and purified water or an acidic solution are mixed, magnesium mesh is injected into individual molding molds, and then irradiated with ultraviolet rays to crosslink the hydrogel (S101), osteoclast growth inhibitor and osteoblast cells A dilution step of diluting at least one selected from the group consisting of growth promoters in purified water or physiological saline (S103) and the dilution solution prepared through the dilution step (S103) of the hydrogel prepared through the hydrogel preparation step (S101). It consists of a hydrogel drug loading step (S105) of loading the drug by impregnating it.

The hydrogel preparation step (S101) is 2-hydroxyethyl methacrylate, methacrylic anhydride, polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2,2-dimethoxy-2-phenylacetophenone, And mixing purified water or an acidic solution and injecting it into a mold with a magnesium mesh interposed therebetween, followed by irradiation of ultraviolet rays to crosslink, 57 to 87% by weight of 2-hydroxyethyl methacrylate and 1.5 to 2.5% by weight of methacrylic anhydride. Weight%, 8 to 32% by weight of polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2 to 8% by weight of 2,2-dimethoxy-2-phenylacetophenone, and the remaining amount of purified water or acidic solution are mixed, and magnesium After the mesh is injected into individual molds, ultraviolet rays having a wavelength of 360 to 370 nm are irradiated for 15 to 25 minutes.

The acidic solution that can be used in the hydrogel preparation step (S101) is an acidic solution of pH 1 to 5, preferably pH 1 to 4, more preferably pH 1 to 3, and even more preferably pH 1.5 to 2.5. . The acid may be hydrochloric acid, sulfuric acid, acetic acid or the like, preferably hydrochloric acid.

The ultraviolet irradiation of the hydrogel manufacturing step (S101) is characterized in that it is made by irradiating ultraviolet rays having a wavelength of 360 to 370 nm for 15 to 25 minutes.

Since the physical properties and efficacy of the magnesium mesh used in the above process and the hydrogel prepared through the above process are the same as those described in the bone generating composition for implant placement, a description thereof will be omitted.

The dilution step (S103) is a step of diluting at least one selected from the group consisting of an osteoclast growth inhibitor or an osteoblast proliferation promoter in purified water or physiological saline, wherein the osteoclast growth inhibitor osteoclast proliferation inhibitor is added to 100 parts by weight of purified water. And it consists of a process of mixing and diluting at least one selected from the group consisting of osteoblast proliferation promoters in 1 to 1.5 parts by weight.

At this time, since the detailed description of the osteoclast growth inhibitor or osteoblast growth promoter is the same as that described in the composition for inducing osteogenesis of the implant placement unit, a description thereof will be omitted.

The hydrogel impregnation step (S105) is a step of impregnating the hydrogel prepared through the hydrogel manufacturing step (S101) into the diluent prepared through the dilution step (S103), the hydrogel manufacturing step (S101) It consists of a process of impregnating the hydrogel prepared through the dilution prepared through the dilution step (S103) for 20 to 30 hours.

After the hydrogel impregnation step (S105) consisting of the above process, bisphosphonate and denosumab, which are osteoclast growth inhibitor components diluted through the dilution step (S103), or osteoblast growth promoter components, teriparapide and strontium lane Leat et al. are absorbed into a plurality of pore layers present in the hydrogel, and osteoclast growth inhibitors and/or osteoblast growth promoters such as bisphosphonate and denosumab absorbed into the pore layer are slowly released to have an osteoclast proliferation inhibitory effect, It is possible to provide a composition for inducing osteogenesis in which the effect of promoting osteoblast proliferation and the effect of preventing osteoporosis lasts for a long period of time.

In addition, between the hydrogel manufacturing step (S101) and the hydrogel impregnation step (S103), the hydrogel prepared through the hydrogel manufacturing step (S101) is immersed in distilled water for 70 to 75 hours to remove unreacted substances The unreacted material removal step (S102) may be further progressed. When the hydrogel prepared through the hydrogel manufacturing step (S101) is impregnated with distilled water to remove the unreacted material, the unreacted material is eluted and ingested into the body. , It is possible to provide a composition for inducing osteogenesis that is harmless to the human body by blocking side effects that disturb the endocrine system in the body.

Hereinafter, the manufacturing method of the composition for inducing osteogenesis in the implant placement part according to the present invention and the physical properties of the composition for inducing osteogenesis manufactured through the manufacturing method will be described with examples.

<Example 1>

87 g of 2-hydroxyethyl methacrylate, 2 g of methacrylic anhydride, 2 g of polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 1 g of 2,2-dimethoxy-2-phenylacetophenone, and 8 g of purified water were mixed to obtain After preparing the mixture, and injecting the mixture into a mold made of silicon interposed with a magnesium mesh having a width of 10 mm × a length of 10 mm × a thickness of 60 μm, ultraviolet rays having a wavelength of 365 nm were irradiated for 20 minutes to form individual magnesium meshes inside. A hydrogel having a diameter of 10 mm × a thickness of 100 μm was prepared, and the hydrogel was immersed in distilled water for 72 hours to remove unreacted substances. A composition for inducing osteogenesis in the implant placement area was prepared by impregnating the mixed diluted solution for 24 hours.

<Example 2>

Proceed in the same manner as in Example 1,

77 g of 2-hydroxyethyl methacrylate, 2 g of methacrylic anhydride, 4 g of polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 1 g of 2,2-dimethoxy-2-phenylacetophenone, and 16 g of purified water were mixed. A composition for inducing osteogenesis in the implant placement area was prepared.

<Example 3>

Proceed in the same manner as in Example 1,

67 g of 2-hydroxyethyl methacrylate, 2 g of methacrylic anhydride, 6 g of polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 1 g of 2,2-dimethoxy-2-phenylacetophenone, and 24 g of purified water were mixed A composition for inducing osteogenesis in the implant placement area was prepared.

<Example 4>

Proceed in the same manner as in Example 1,

57 g of 2-hydroxyethyl methacrylate, 2 g of methacrylic anhydride, 8 g of polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 1 g of 2,2-dimethoxy-2-phenylacetophenone, and 32 g of purified water were mixed. A composition for inducing osteogenesis in the implant placement area was prepared.

The amount of release of sodium ibandronate, an osteoclast growth inhibitor, contained in the composition for inducing osteogenesis of the implant placement part prepared in Examples 1 to 4 was measured and shown in Table 1 and FIG. 4 below.

{However, the amount of sodium ibandronate released was measured by a UV-Vis spectrophotometer (UV-Vis spectrophotometer, Nano-MD, Sinco) was used to quantitatively measure at the wavelength accuracy ±1 nm precision.}

<Table 1>

As shown in Table 1 and FIG. 4 below, the composition for inducing osteogenesis in the implant placement part prepared in Examples 1 to 4 of the present invention shows that sodium ibandronate, an osteoclast growth inhibitor, is stably released for a long time. Able to know.

Therefore, the composition for inducing osteogenesis in the implant placement part according to the present invention and the manufacturing method thereof according to the present invention are applied to the jawbone where the implant is placed to suppress the proliferation of osteoclasts and promote the proliferation of osteoblasts, thereby increasing the rate of bone regeneration and Because it improves bone density, it shows the effect of improving the implant placement efficiency.

10; base layer
20; cortex
S101; Hydrogel manufacturing step
S102; Unreacted material removal step
S103; dilution step
S105; Hydrogel impregnation step

Claims (9)

A substrate layer made of magnesium mesh; and
It is formed on at least one of the outer and inner surfaces of the substrate layer and is formed of a hydrogel containing at least one selected from the group consisting of an osteoclast growth inhibitor and/or an osteoblast growth promoter. A composition for inducing osteogenesis in the implant placement part,
The hydrogel is 2-hydroxyethyl methacrylate, methacrylic anhydride, polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2,2-dimethoxy-2-phenylacetophenone, and purified water or acid solution Composition for inducing osteogenesis of the implant placement part, characterized in that consisting of. The method of claim 1,
The hydrogel contains 57 to 87% by weight of 2-hydroxyethyl methacrylate, 1.5 to 2.5% by weight of methacrylic anhydride, 8 to 32% by weight of polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2,2 -Dimethoxy-2-phenylacetophenone 2 to 8% by weight, and a composition for inducing osteogenesis in the implant placement part, characterized in that consisting of the remaining amount of purified water or acidic solution. The method of claim 1,
The osteoclast growth inhibitor is a composition for inducing osteogenesis of an implant placement part, characterized in that consisting of at least one selected from the group consisting of bisphosphonate and denosumab or strontium ranelate. The method of claim 1,
The osteoblast proliferation promoter is a composition for inducing osteogenesis of an implant placement part, characterized in that consisting of one or more selected from the group consisting of teriparatide and strontium ranelate. 2-Hydroxyethyl methacrylate, methacrylic anhydride, polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2,2-dimethoxy-2-phenylacetophenone, and purified water or acidic solution were mixed and magnesium A hydrogel manufacturing step of crosslinking by irradiating ultraviolet rays after injection into a mold having a mesh interposed therebetween;
A dilution step of diluting at least one selected from the group consisting of osteoclast proliferation inhibitors and/or osteoblast proliferation promoters in purified water or physiological saline; and
A hydrogel impregnation step of impregnating the hydrogel prepared through the hydrogel manufacturing step into the diluent prepared through the dilution step; Method for producing a composition for inducing osteogenesis of an implant placement part, characterized in that consisting of. The method of claim 5,
The hydrogel preparation step includes 57 to 87% by weight of 2-hydroxyethyl methacrylate, 1.5 to 2.5% by weight of methacrylic anhydride, 8 to 32% by weight of polyethylene oxide-polypropylene oxide-polyethylene oxide terpolymer, 2 A method for producing a composition for inducing osteogenesis in an implant placement part, characterized by mixing 2 to 8% by weight of 2-dimethoxy-2-phenylacetophenone and the remaining amount of purified water or an acidic solution. The method of claim 5,
The ultraviolet irradiation is a method for producing a composition for inducing osteogenesis of an implant placement part, characterized in that made by irradiating ultraviolet rays having a wavelength of 360 to 370 nm for 15 to 25 minutes. The method of claim 5,
The hydrogel impregnation step is a method for producing a composition for inducing osteogenesis of an implant placement part, characterized in that made for 20 to 30 hours. The method of claim 5,
Between the hydrogel production step and the hydrogel impregnation step, an unreacted material removal step of removing unreacted materials by immersing the hydrogel prepared through the hydrogel production step in distilled water for 70 to 75 hours is further progressed A method for producing a composition for inducing osteogenesis of an implant placement part.

Images